Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 12Unknown 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 12Neuroendocrine Tumors 5Neoplasm Metastasis 5Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Adenoma, Islet Cell 3Recurrence 2Meningioma 2Glioblastoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Thymus Neoplasms 1Sarcoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphangioleiomyomatosis 1Locally Advanced Thyroid Gland Carcinoma 1Kidney Neoplasms 1HR+/HER2- Advanced Breast Cancer 1Glioma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Gallbladder Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

Sirolimus 2exemestane 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Phlebotomy 1Injections 1Genetic Testing 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Tuberous Sclerosis × Everolimus × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡